soul trial oral semaglutide cardiovascular outcomes 2024 SOUL: Bests Usual Care in High-Risk Type 2 Diabetes Heart and SOUL – oral
Description
FDA approval is anticipated in 2026, through the FDA's national priority voucher program, positioning Lilly to compete aggressively in the oral segment
They will offer special nutrition products
GIP and GLP-1 also regulate glucagon secretion, through direct and indirect pathways
It is often described as an adaptogen because it helps the body adapt to stress
When GLP-1 drugs scaled in the US, something strange started happening to completely unrelated industries
Citations: World Health Organization
